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Background: In a previous report, we described the in vitro and in vivo antiproliferative and proapoptotic activity of
a hydroxylated biphenyl (D6), a structural analogue of curcumin, on malignant melanoma and neuroblastoma
tumours. In this paper, we investigated the molecular changes induced by such a compound, underlying cell
growth arrest and apoptosis in melanoma cells.
Results: To shed light on the mechanisms of action of D6, we firstly demonstrated its quick cellular uptake and
subsequent block of cell cycle in G2/M phase transition. A gene expression profile analysis of D6-treated melanoma
cells and fibroblasts was then carried out on high density microarrays, to assess gene expression changes induced
by this compound. The expression profile study evidenced both an induction of stress response pathways and a
modulation of cell growth regulation mechanisms. In particular, our data suggest that the antiproliferative and
proapoptotic activities of D6 in melanoma could be partially driven by up-regulation of the p53 signalling pathways
as well as by down-regulation of the PI3K/Akt and NF-kB pathways. Modulation of gene expression due to D6
treatment was verified by western blot analysis for single proteins of interest, confirming the results from the gene
expression profile analysis.
Conclusions: Our findings contribute to the understanding of the mechanisms of action of D6, through a
comprehensive description of the molecular changes induced by this compound at the gene expression level, in
agreement with the previously reported anti-tumour effects on melanoma cells.Background
Melanoma is the most aggressive form of skin cancer. Its
incidence and mortality have risen dramatically in all de-
veloped countries during the last half century [1]. Although
most cases of melanoma are diagnosed early and surgically
resected, later stages of this tumour have very poor survival
rates because of the lack of available effective therapies
[1-3]. Recently, promising therapeutic approaches for mel-
anoma management have been introduced into the clinical
practice, based mostly on the use of small-molecule inhibi-
tors directed against oncogenic molecular targets as well as
on immunotherapy [4-7]. However, a high molecular het-
erogeneity of melanoma tumours and a complex network* Correspondence: carla.rozzo@icb.cnr.it
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reproduction in any medium, provided the orof proliferation and survival pathways involved in its
pathogenesis have been reported [8,9]. For this reason,
there is a growing interest in seeking pharmacological
agents that could target multiple gene products in order to
interfere, at different levels, with pathogenetic pathways in
melanoma. During the last decades, several dietary agents
have been reported to exert anticancer activity. They com-
monly show multifaceted effects on cancer cells by indu-
cing molecular changes related to different mechanisms of
carcinogenesis: proliferation, apoptosis, invasion, and me-
tastasis [10]. An innovative therapeutic approach to man-
age melanoma may be represented by the introduction
into clinical trials of naturally occurring compounds (such
as eugenol, resveratrol, green tea, curcumin and other),
whose antiproliferative and/or proapoptotic activity
against malignant melanoma - in both in vitro and in vivo
models - has been already demonstrated [11]. Among
them, curcumin, a polyphenol extracted from the rhizometd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to exert promising anticancer activity on several tumours
[12]. This molecule is highly pleiotropic, is able to enter
cells [13], and interacts with numerous targets [14]. Strong
evidence demonstrated that curcumin inhibits prolifera-
tion, invasion, angiogenesis, and metastasis in several
types of cancer through interaction with multiple cell sig-
nalling proteins (reviewed in [15,16]). Recently, curcumin
has been shown to exert a good antiproliferative activity
by inducing apoptosis in malignant melanoma [17]. One
of the most important pathway involved in the curcumin
antitumour activity is the nuclear factor-kB (NF-kB) path-
way [18], particularly in melanoma cells. Indeed, curcumin
is able to suppress the activation and phosphorylation of
the inhibitor of NF-kB alpha (IkBa) by inhibiting the IkB
kinase (IKK) and NF-kB activity in human melanoma cell
lines [19,20]. Moreover, curcumin induces cell apoptosis
and cell cycle arrest in G2/M phase in melanoma, through
up-regulation of p53, p21, p27 and checkpoint kinase
2 [19].
Recently, our group has synthesized a new curcumin-
related biphenyl structure (an αβ unsaturated ketone called
D6) whose antiproliferative and proapoptotic activities on
melanoma cell lines were more effective, rapid and selective
than those induced by curcumin. The D6 compound was
proved to promote apoptosis in melanoma cells through
the mitochondrial intrinsic pathway [21]. In vivo assays on
mouse models confirmed the potential of D6 against mel-
anoma, showing a significant reduction of the tumour mass
growth as compared to untreated control [21].
To investigate the mechanisms of action of the D6-
curcumin analogue against melanoma at the molecular
level, we here studied its cellular uptake and its influence
on cell cycle progression. Finally, a gene expression profile
analysis of D6-treated melanoma cell lines was carried out
on high density microarrays, in order to explore the mo-
lecular pathways activated after D6 enters cells. This gen-
omic technology is useful to dissect the molecular changes
occurring inside cancer cells, and it is well documented for
malignant melanoma [22,23]. In our study, the LB24Dagi
(LB24) primary melanoma cell line was selected for all the
analyses, because it had been previously demonstrated to
be the most sensitive line to D6 treatment among tested
ones [21]. Several molecular changes that can justify the
antiproliferative and proapoptotic properties of D6 on mel-
anoma cells and likely contribute to its anti-tumour effect
have been here presented and discussed.
Results
D6 enters melanoma cells
To verify the ability of D6 (Figure 1A) to enter melanoma
cells, as demonstrated for curcumin in different cancer
cells [13], we performed cellular uptake studies. After a 24
hours time course treatment, D6 cellular uptake wasestimated by LC-MS on methanol cell lysates, as described
in Methods. Comparison of D6 peak area for each sample
to a calibration curve allowed us to calculate intracellular
D6 concentration at different times. Data reported in
Figure 1B show that the highest cellular D6 concentration
(about 270 nM, corresponding to approximately 600
pmoles/106 cells) was reached two hours after treatment.
These results indicated that D6 presents the same time of
uptake of curcumin in other cancer cells and is able to
enter melanoma cells about 15 folds more efficiently than
curcumin itself (34–44 pmoles/106 cells [13]).
D6 blocks cell cycle at G2/M transition
To evaluate the effect of D6 treatment on melanoma cell
cycle progression, we performed flow cytofluorimetric ana-
lysis on LB24 cells treated with either 5 or 10 μM D6 for
24 hours and stained with propidium iodide, as described
in Methods. Results obtained are summarized in Figure 2.
A significant enrichment in G2/M cell populations was
observed at both 5 μM (21.65%) and 10 μM (26.13%) con-
centrations of D6 treatment, as compared to untreated
cells (11.0%) (P < 0.05 and < 0.001 respectively) (Figure
2A). As a consequence, a significant reduction of G0/G1
phase cell population confirms the cell cycle arrest in G2
as an effect of melanoma cells exposure to D6. Figure 2B
shows representative cell cycle histograms with a consist-
ent increase in S phase cell number, indicating an accumu-
lation of cells that do not trespass the G2/M checkpoint.
Altogether, such findings strongly suggest that block of cell
cycle progression may represent one of the mechanisms by
which D6 inhibits melanoma cells growth (as previously
observed by our group [21]).
D6 treatment induces transcriptional changes in
melanoma cells and normal fibroblasts
To analyze gene expression modifications induced by D6
treatment on melanoma cells, we carried out gene expres-
sion profile analyses on LB24 primary melanoma cell line,
either treated or not (negative control) with 10 μM D6,
using high density microarrays (see Methods). Same ana-
lysis was performed on human fibroblasts cells (BJ cell
line) as normal control, which have been previously dem-
onstrated to be insensitive to D6 [21].
Gene expression results were firstly filtered, in order
to avoid analysis of background detection values (see
Methods). Overall, 18,798 probes, representing the ef-
fective gene expression profiles of cell populations ex-
amined, were selected to perform the statistical analysis.
This allowed the identification of gene transcripts
whose expression was modulated by D6 treatment in
each of the two cell types. Gene expression values
obtained from D6 treated cells were compared with
those obtained from untreated cells and fold change
values (FC) were determined. For each cell population,
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Figure 1 D6 cellular uptake. A: molecular structure of the curcumin-related biphenyl compound, the αβ-unsaturated ketone D6 (3E,3'E)-4,
4'-(5,5',6,6'-tetramethoxy-[1,1'-biphenyl]-3,3'-diyl)bis(but-3-en-2-one); B: intracellular D6 mean concentrations following incubation of LB24 cells with
10 μM D6 for the indicated times. Mean values were calculated by the LC/MS method.
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more, over-expression) or under 0.5 (half intensity or less,
under-expression) (0.5 > FC > 2) among treated and un-
treated samples were selected. Such comparison resulted in
two lists of genes differentially expressed in either LB24
melanoma cells [1,173 probes (719 genes, excluding redun-
dancies); 6.2% of the 18,798 analysed ones] (Additional file
1-A) and in BJ fibroblast [1,883 probes (1,177 genes, ex-
cluding redundancies); 10%] (Additional file 2-A). In par-
ticular, 3.6% and 2.6% analysed transcripts were over- and
under-expressed in melanoma cells, respectively. In fibro-
blasts, the trend of percentages was instead opposite (5.2%
under- and 4.8% over-expressed transcripts) (Table 1).
The two lists of selected probes were analysed by the In-
genuity Pathway Analysis (IPA) software. Results obtainedA G0/G1
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Figure 2 Cell cycle progression analysis. Cytofluorimetric analysis results
summarizes the percentage mean values ± SD of each cell cycle phase cell po
performed independently for each phase considering untreated (0 μM) versus
B: DNA content frequency histograms representing cells from untreated (0 μM
one, representative of three independent experiments.on melanoma cells are reported in Additional file 1-B and
1-C. IPA results obtained for BJ fibroblasts are reported in
Additional file 2-B and 2-C.
D6 treatment affects cell death and proliferation bio-
functions
The top bio-functional categories identified by IPA among
the genes modulated in treated melanoma cells are listed
in Table 2, where the p-values range and number of mole-
cules involved are reported for each category (see the
complete list in Additional file 1-B).
The lowest p-values were found for the Cell Death cat-
egory with 194 molecules involved (Table 2, n. 1). Cell
death is indeed the primary effect detected on melanoma
cells after D6 treatment [21]. Moreover, a variable numberG2/M
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pulations, obtained in three independent experiments. T-test was
treated (5 and 10 μM D6 respectively) cells. * P< 0.05 , ** P< 0.001;
) or 5 and 10 μM D6 treated LB24 cells. The histograms are referred to
Table 1 Transcriptional changes induced by D6 treatment
in melanoma cells and normal fibroblasts
Cell type Differentially
expressed transcripts
Over-
expressed
Under-
expressed
(0.5 > FC > 2) (FC > 2) (FC < 0.5)
LB 24 DAGI
Melanoma cells
1173 (6.2%) 681 (3.6%) 492 (2.6%)
BJ Fibroblasts 1883 (10%) 910 (4.8%) 973 (5.2%)
Results from the statistical analysis conducted on microarrays gene expression
data from LB24 melanoma cells and BJ fibroblasts, treated or not with 10 μM
D6, are reported. Data shown represent the number / (percentages) of human
transcripts that resulted differentially expressed (0.5 > FC > 2) by comparing
treated and not treated samples. Detailed gene expression profile and
statistical analysis procedures are described in the Methods section.
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tional categories strictly correlated with cell proliferation
processes such as cellular function and maintenance, cell
cycle and cell growth and proliferation (Table 2, n. 2–5).D6 induces stress response pathways and down-regulates
cell proliferation pathways
Table 3 lists the most significant pathways (p < 0.05) that
IPA found to be enriched with the input genes in melan-
oma cells (a complete list is reported in Additional file 1-
C). For each pathway, the respective nominal p-value,
along with all the input molecules are reported (Table 3).
A general trend of up-regulation for pathways involving
cell stress response was evident (Figure 3, red bars); con-
versely, pathways that control cell proliferation appeared
down-regulated (Figure 3, green bars).
The first three most significant pathways, 1-Aldosterone
signalling, 2-Protein ubiquitination, and 3-NRF2 mediated
oxidative stress response as well as the 21-Endoplasmic
reticulum stress pathway appear to be up-regulated (Table 3;
Figure 3), depicting a strong activation of stress induced
molecular responses that involves over-expression of heat
shock proteins (HSPs) and activation of protein degradation
processes. Among up-regulated HSPs, HSPA6 is the most
over-expressed transcript in melanoma treated cells with aTable 2 Melanoma top bio functions
Bio-Function p-value N. of molecules
1 Cell death 3.34E-15 – 3.24E-02 194
2 Cellular function
and maintenance
6.17E-14 – 3.24E-02 64
3 Cancer 1.22E-13 – 3.24E-02 306
4 Cell cycle 9.64E-12 – 3.15E-02 113
5 Cellular growth and
proliferation
1.16E-11 – 3.15E-02 204
Top five bio-functional categories identified by IPA software by analysing the
1,173 transcripts modulated in 10 μM D6 treated LB24 melanoma cells are
reported. The p-value reflects the significance of the enrichment of input genes in
each functional category. The complete list is reported in Additional File 1-B.FC value of 368.61 (Table 4). HSPA6 codifies for the
Hsp70B’, a highly stress inducible protein.
Additional pathways such as 4 -Cell cycle: G2/M DNA
damage checkpoint regulation, 5 -p53 signalling, 10 -Her-
editary breast cancer signalling, 11 -ATM signalling, 26 -
Role of BRCA1 in DNA damage response, and 27 -Role of
CHK proteins in cell cycle checkpoint control are all related
to DNA repair mechanisms and cell death triggering
(Table 3 and Additional files 3, 4, 5, 6, 7, 8), evidencing a
DNA damage as cell response to D6 treatment.
The up-regulation of pathway 5- p53 signalling (Figure 3,
Additional file 4), which acts in response to cell injury or
DNA damage by controlling cell proliferation and driving
cells to apoptosis, is noteworthy and points out a central
role of this regulatory protein in the D6 anticancer effect
on melanoma cells. Indeed, induction of p53 activity was
evidenced by up-regulation of some p53 target genes:
CDKN1A (FC = 19.35), GADD45A and B (FC = 7.78 and
FC = 7.47, respectively), all codifying for inhibitors of the
cell cycle, and PMAIP1 (FC = 6.08) codifying for Noxa, a
pro-apoptotic BH3 only protein of the Bcl2 family (Table 4).
A slight up-regulation of TP53BP2 gene (FC = 2.36), codi-
fying for ASSP2 - a member of the ASPP (apoptosis-stimu-
lating protein of p53) family of p53 interacting proteins,
confirms the role of p53 as an apoptosis activator in our
system.
Down-regulation of pathways controlling cell prolifera-
tion such as pathways 4-Cell cycle:G2/M DNA damage
checkpoint regulation, 8 -Mitotic roles of PLK, 13 -Cyclins
and cell cycle regulation, 23 -Molecular mechanisms of can-
cer and 25 -Cell cycle: G1/S checkpoint regulation was also
observed (Figure 3, green bars). These alterations seem to
be related to the down-regulation of important cell-cycle
“motors” like CCNB1/2 (cyclin B1 and 2), CDC25, and
CDK4 (Tables 3 and 4, Additional files 3, 9, 10, 11, 12).
Other interesting features highlighted by the pathway
analysis are the partial down regulation of phospha-
tidylinositol 3 kinase - regulatory subunit 2 (PIK3R2, FC =
0.48) and nuclear factor-kB1 (NFKB1, FC = 0.47) genes
(Table 4). On this regard, both PIK3R2 and NFKB1 are
greatly represented in the melanoma most significant
pathways listed in Table 3 (19 and 13 out of 42 pathways,
respectively).
D6 modulates the expression of several life and death
regulator genes
Beside the modulated genes highlighted by the pathway
analysis, FC analysis evidenced some other genes whose
modulation might have a role in the observed anti-
proliferative and pro-apoptotic activities of D6 on melan-
oma cells (Additional file 1-A) [21]. Among them, the
CCNF gene that codifies for the G2/mitotic-specific
cyclin-F was highly down-modulated (FC = 0.24, Table 4).
Cyclin F is produced in the G2 cell cycle phase and is
Table 3 Melanoma top canonical pathways
Ingenuity canonical pathways Nominal p-value Genes
1 Aldosterone Signaling in
Epithelial Cells
2.81838E-06
CRYAB,HSPA7,SGK1,DNAJB4,HSPA1A/HSPA1B,HSPH1,SLC12A2,HSPA6, DNAJC3,
HSPD1,DNAJB2,DNAJB9,HSPA5,DNAJA1,DNAJB14,HSPA4,HSPA1L,DUSP1,HSPA13,
PIK3R2,DNAJB6,DNAJB1,HSPA4L
2 Protein Ubiquitination Pathway 3.98107E-06
CRYAB,UBE2H,HSPA7,DNAJB4,HSPA1A/HSPA1B,HSPA6,DNAJC3,DNAJB2, HSPA5,
DNAJA1,HSPA4,HSPA1L,STUB1,HLA-B, DNAJB1, BRCA1, HSPA4L, MED20, HSPH1,
PSMC4, USP30, HSPD1, DNAJB9, DNAJB14, SKP2 (includes EG:27401), ANAPC4, PSMD12,
HSPA13, DNAJB6, UBC, UBE2D3
3 NRF2-mediated Oxidative
Stress Response
7.58578E-05
NRAS,DNAJB4,HERPUD1,DNAJC3,DNAJB2,DNAJA1,DNAJB9,DNAJB14,MAFF, TXNRD1,
FOS, HMOX1, JUN, ATF4, MAP2K3, FOSL1, PIK3R2, SQSTM1, DNAJB6, DNAJB1, GCLM, EIF2AK3
4 Cell Cycle: G2/M DNA Damage
Checkpoint Regulation
0.000177828
CDC25B, GADD45A, CDKN1A, TOP2A, CCNB2, PKMYT1, BRCA1, SKP2 (includes EG:27401),
CCNB1
5 p53 Signaling 0.000194984 PMAIP1, GADD45B, THBS1, TNFRSF10B, TP53BP2, SERPINE2, SCO2 (includes EG:606683),
JUN, GADD45A, CDK4, ADCK3, CDKN1A, PIK3R2, BRCA1
6 VDR/RXR Activation 0.000446684 GTF2B,LRP5, GADD45A, MXD1, HOXA10, CDKN1A, IGFBP3, CD14, CST6 (includes EG:1474),
CSF2, RXRA, KLF4
7 Pyrimidine Metabolism 0.001 POLE2, DCTPP1, UPP1, POLQ, DKC1, DTYMK, RFC5, POLRMT, PUS1, TXNRD1, POLR1C, POLD3,
PNP, POLA2, UNG, ENTPD7
8 Mitotic Roles of Polo-Like
Kinase
0.002089296 CDC25B, PPP2CB, ANAPC4, PLK2, CDC7 (includes EG:12545), CCNB2, PKMYT1, ANAPC13, CCNB1
9 IGF-1 Signaling 0.002818383 SOCS1, CSNK2A2, FOS, JUN, NRAS, CTGF, NOV, IGFBP3, PRKAG2, IRS2, PIK3R2, CYR61
10 Hereditary Breast Cancer
Signaling
0.003467369
NRAS, GADD45B, FANCG, RFC5, CCNB1, PALB2, GADD45A, CDK4, XPC, CDKN1A, PIK3R2,
UBC, BRCA1
11 ATM Signaling 0.003890451 JUN, GADD45B, GADD45A, CDKN1A, CCNB2, ATF4, BRCA1, CCNB1
12 RAR Activation 0.004265795 RDH14, BMP2 ,CSK, ADCY3, SMAD5, NFKB1, VEGFA, FOS, CSNK2A2, JUN, TAF4 (includes
G:100149942), DUSP1, CRABP2, IGFBP3, PRKAG2, PIK3R2, RXRA
13 Cyclins and Cell Cycle
Regulation
0.004677351 PPP2CB, E2F6, TFDP1, CDK4, SUV39H1, CDKN1A, E2F5, CCNB2, SKP2 (includes EG:27401), CCNB1
14 p38 MAPK Signaling 0.005495409 FADD, DDIT3, DUSP1, DUSP10, MEF2D, H3F3A/H3F3B, ATF4, MAP2K3, MKNK2, EEF2K,
H3F3C, IRAK2
15 Pancreatic Adenocarcinoma
Signaling
0.005888437 VEGFA, HMOX1, E2F6, TFDP1, CDK4, SUV39H1, CDKN1A, E2F5, HBEGF, PIK3R2, ERBB2, NFKB1
16 Renal Cell Carcinoma Signaling 0.00691831 VEGFA,ETS1,FOS,JUN,NRAS,SLC2A1,CRK,PIK3R2,UBC
17 Cell Cycle Regulation by BTG
Family Proteins
0.00691831 PPP2CB,E2F6,CDK4,E2F5,BTG1,CCRN4L
18 Retinoic acid Mediated
Apoptosis Signaling
0.007585776 FADD,TNKS,CRABP2,TNFRSF10B,TNFRSF10D,RXRA,TIPARP,IRF1 (includes EG:16362)
19 Glucocorticoid Receptor
Signaling
0.008912509
IL8,NRAS,HSPA7,SGK1,HSPA1A/HSPA1B,HSPA6,NFKB1,HSPA5,TAF13 (includes EG:310784),
FOS,HSPA4,GTF2B,TAF6L,JUN,TAF4 (includes EG:100149942),HSPA1L,DUSP1,CDKN1A,FKBP4,
PRKAG2,PIK3R2,CSF2
20 Toll-like Receptor Signaling 0.01023293 FOS,LY96 (includes EG:17087),JUN,CD14,MAP2K3,NFKB1,IRAK2
21 Endoplasmic Reticulum Stress
Pathway
0.010715193 DNAJC3,ATF4,HSPA5,EIF2AK3
22 Neurotrophin/TRK Signaling 0.013489629 FOS,JUN,NRAS,SPRY1,ATF4,MAP2K3,PIK3R2,FRS2
23 Molecular Mechanisms
of Cancer
0.015488166
BMP4,SUV39H1,BMP2,CRK,SMAD5,NFKB1,CDC25B,E2F6,JUN,E2F5,PIK3R2,BRCA1,LRP5,
PMAIP1,NRAS,STK36,TFDP1,ADCY3,AURKA,FADD,FOS,RND3,CDK4,CDKN1A,PRKAG2,MAP2K3
24 Chronic Myeloid Leukemia
Signaling
0.015848932 E2F6,NRAS,TFDP1,CDK4,SUV39H1,CDKN1A,E2F5,CRK,PIK3R2,NFKB1
25 Cell Cycle: G1/S Checkpoint
Regulation
0.016982437 E2F6,TFDP1,CDK4,SUV39H1,CDKN1A,E2F5,SKP2 (includes EG:27401)
26 Role of BRCA1 in DNA Damage
Response
0.018620871 E2F6,GADD45A,FANCG,CDKN1A,E2F5,RFC5,BRCA1
27 Role of CHK Proteins in Cell
Cycle Checkpoint Control
0.022387211 E2F6,CDKN1A,E2F5,RFC5,BRCA1
28 Bladder Cancer Signaling 0.028840315 VEGFA,IL8,NRAS,TFDP1,THBS1,CDK4,SUV39H1,CDKN1A,ERBB2
29 IL-17A Signaling in Gastric Cells 0.033113112 IL8,FOS,JUN,NFKB1
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Table 3 Melanoma top canonical pathways (Continued)
30 Role of Tissue Factor in Cancer 0.036307805 VEGFA,IL8,NRAS,CTGF,ARRB1,PLAUR,HBEGF,PIK3R2,CSF2,CYR61
31 HMGB1 Signaling 0.038904514 IL8,FOS,JUN,NRAS,RND3,MAP2K3,PIK3R2,NFKB1,KAT2A
32 ERK/MAPK Signaling 0.039810717 ETS1,NRAS,H3F3A/H3F3B,CRK,MKNK2,PPP1R14B,H3F3C,FOS,PPP2CB,ELF3,DUSP1,PRKAG2,ATF4,
DUSP4,PIK3R2
33 Non-Small Cell Lung Cancer
Signaling
0.041686938 NRAS,TFDP1,CDK4,SUV39H1,PIK3R2,ERBB2,RXRA
34 Prostate Cancer Signaling 0.041686938 NRAS,TFDP1,SUV39H1,CDKN1A,NKX3-1,ATF4,PIK3R2,NFKB1
35 RAN Signaling 0.042657952 CSE1L,XPO1,RANBP1
36 Cell Cycle Control of
Chromosomal Replication
0.042657952 MCM3,CDK4,ORC5 (includes EG:26429),CDC7 (includes EG:12545)
37 IL-6 Signaling 0.043651583 IL8,SOCS1,CSNK2A2,FOS,JUN,NRAS,CD14,MAP2K3,NFKB1
38 IL-2 Signaling 0.046773514 SOCS1,CSNK2A2,FOS,JUN,NRAS,PIK3R2
39 MIF Regulation of Innate
Immunity
0.046773514 FOS,LY96 (includes EG:17087),JUN,CD14,NFKB1
40 Role of IL-17F in Allergic
Inflammatory Airway Diseases
0.046773514 IL8,ATF4,SIK1,CSF2,NFKB1
41 Erythropoietin Signaling 0.047863009 SOCS1,FOS,PTPN6,JUN,NRAS,PIK3R2,NFKB1
42 Estrogen Receptor Signaling 0.048977882 TAF6L,GTF2B,NRAS,TAF4 (includes EG:100149942), MED20, H3F3A/H3F3B, MED16,HNRNPD,
TAF13 (includes EG:310784),MED10,H3F3C
Most significant pathways (nominal p-value < 0.05) identified by IPA software by analysing the 1,173 transcripts modulated in 10 μM D6 treated LB24 melanoma
cells are reported. The p-value reflects the significance of the enrichment of input genes in each pathway. The complete list is reported in Additional File 1-C.
Genes discussed in the text and HSPs are evidenced by bold characters.
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http://www.molecular-cancer.com/content/12/1/37essential for fidelity of mitosis; therefore, a down-
modulation of such protein may interfere with the progres-
sion of cell division, which is consistent with the block of
cell cycle in G2/M phase observed upon D6 treatment
(Figure 2).
Among the down-regulated genes (FC < 0.5), we found
an evident under-expression of the c-KIT proto-oncogene
(FC = 0.30), whose activation is often associated withDownregulated
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Numbers on top of the columns represent the total number of genes invoincreased cell proliferation, specifically in melanoma
(Table 4) [24]. Down regulation of c-KIT is then likely to
be related to D6 anticancer activity on melanoma cells,
contributing to inhibit cell-proliferation signals.
We already demonstrated that D6 treatment induces
apoptosis in melanoma cells through the mitochondrial
intrinsic pathway [21]. Looking at gene expression levels
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Table 4 Melanoma modulated genes
GENE FC
LB BJ
HSPA6 368.61 480.00
HSPA1A 20.35 12.38
CDKN1A 19.35 4.29
DDIT3 11.11 9.11
GADD45A 7.78 6.00
GADD45B 7.47 14.90
PMAIP1 6.08 7.72
BCL10 3.93 2.02
TP53BP2 2.36 –
CCNF 0.24 –
KIT 0.30 –
CDK4 0.43 0.43
CCNB1 0.43 –
CDC25B 0.47 –
NFKB1 0.47 –
PIK3R2 0.48 –
Genes differentially expressed in LB24 melanoma cells after D6 treatment are
reported. The most significant genes possibly related to D6 antiproliferative
and pro-apoptotic effects as well as their relative fold change values (FC) in
either LB24 melanoma cells or BJ fibroblasts are presented. The complete lists
of differentially expressed genes and relative FC for each cell line are reported
in the Additional files 1-A and 2-A respectively.
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http://www.molecular-cancer.com/content/12/1/37regulation of DDIT3 (DNA–damage-inducible transcript
3, FC = 11.1), a transcription factor activated in endoplas-
mic reticulum stress conditions that promotes apoptosis
by induction of caspases [25], as well as a discrete over-
expression of the gene BCL10 (FC = 3.93), encoding for a
pro-apoptotic member of the Bcl2 family proteins [26], in
addition to the over-expression of the protein Noxa codi-
fied by PMAIP1 mentioned above (FC = 6.08) (Table 4).
These are further evidences about the involvement of pro-
apoptotic signals in D6 treated cells.
Expression profile changes in D6 treated fibroblasts
The IPA-based analysis of the 1,883 transcripts modulated
by D6 in fibroblasts (listed in Additional file 2-A) was use-
ful to compare results with those obtained in melanoma
cells. Biological function categories found to be significant
in fibroblasts were similar to those selected for melanoma
cells (Additional file 2-B), suggesting that D6 treatments
involve life and death controlling mechanisms also in nor-
mal cells. However, D6 treated fibroblasts did not show
significant effects in terms of block of proliferation or in-
duction of apoptosis, as we previously described [21].
The analysis of D6 treated fibroblasts evidenced the in-
volvement of the pathways underlying general cell stress
responses (Additional file 2-C). However, processes includ-
ing chaperones activation and protein degradation were
less significant in fibroblasts than in melanoma cells
(Additional file 2-C, pathways 10, 16, 21), with some HSPsbeing down-modulated. Conversely, DNA damage induced
cell response pathways were highly significant in fibroblasts
also (see Additional file 2-C, pathways 2, 3, 4, 5, 9, 18), in-
dicating that D6 even triggers an anti-mitotic reaction in
normal cells (though not confirmed in the biological assays
[21]). Such a response was anyway weaker in these latter
cells and pathway trends markedly differed between mel-
anoma and fibroblasts (i.e., p21/CDKN1A, FC = 19.35 in
melanoma cells versus FC = 4.29 in fibroblasts, or CCNB1,
FC = 0.43 and CDC25B, FC = 0.47 in melanoma cells with
no modulation in fibroblasts; Table 4). Furthermore, nei-
ther PIK3R2 nor NFKB1 gene expressions were altered in
fibroblasts, suggesting that the relative pathways are not
hindered by D6 in these normal cells. These data suggest
that D6 interaction with both PI3K/Akt and NF-kB signal
transduction cascades may be peculiar of its activity on
cancer cells.Protein levels reflect gene expression changes in D6
treated melanoma cells
Protein levels for most of the differentially expressed genes
above mentioned were verified by western blot on LB24
cells (Figure 4), in order to confirm that D6-induced modu-
lation of expression at mRNA levels was indeed maintained
at protein levels.
Figure 4A shows the increased protein levels detected
by western blot for the three major p53 targets modulated
by D6: p21, GADD45A, and Noxa. The p21 protein was
about 2.5 fold more expressed in treated cells compared to
the untreated ones, confirming the increase of CDKN1A
gene expression. Same increased levels were observed for
the GADD45-A protein, while Noxa protein levels were
about 70% higher as compared to those of control cells.
Among the proteins involved in regulation of cell cycle
G2/M phase transition, we performed immunoblot as-
says for cyclin B, cdc25, and cyclin F. Protein levels
detected in D6 treated cells were much lower than those
of untreated ones, thus confirming the decrease of ex-
pression observed in microarrays analysis (Figure 4B).
An almost complete depletion of the PI3K protein in
treated cells compared to untreated ones is shown in Fig-
ure 4C, reflecting the under-expression of the PIK3R2
gene and suggesting a possible down-regulation of PI3K/
Akt pathway. To confirm such an inhibitory effect, we in-
vestigated the Akt activation status and performed an
immunoblot analysis using a specific anti phospho-Akt
antibody. Expression of AKT gene itself was not modu-
lated after D6 treatment (data not shown), but its phos-
phorylation/activation status was decreased of about 75%
(Figure 4C). Down-modulation of c-KIT gene expression
was also confirmed by western blot analysis, which
showed that c-kit protein level was decreased of about
65% (Figure 4C).
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Figure 4 Western blot analysis. Validation by western blotting of selected gene products expression. LB24 melanoma cells were grown to
semi-confluence, treated (+) or not (−) for 24 hours with 10 μM D6, then harvested and lysed as described in Methods. Cell lysates were analysed
by western blotting for the expression levels of selected proteins modulated by D6 treatment: (A) p53 targets: p21, GADD45A and Noxa; (B) cell
cycle regulators: cyclin B, cdc25, cyclin F; (C) growth signals stimulating proteins: PI3K, p-Akt, c-kit; (D) proapoptotic proteins: DDIT3, Bcl10. Protein
levels were quantified by Image J Software and normalized over (ratio) the GAPDH protein levels used as internal control. Data are reported as
percentage of protein expression in D6 treated cells compared to untreated ones (100%).
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http://www.molecular-cancer.com/content/12/1/37Finally, an up-modulation of the DDIT3 and Bcl10 pro-
tein expression levels upon D6 treatment was confirmed
by western blot analysis (Figure 4D).
Discussion
In this paper, we demonstrate that the curcumin analogue
D6 is able to enter melanoma cells reaching a peak in
about two hours (see Figure 1), and give rise to a series of
molecular changes that underlie the previously described
anti-tumour activity of such a compound [21].
Our results indicated that D6 treatment may promote a
block of cell cycle progression in G2 phase (see Figure 2)
and this could represent one of the mechanisms that in-
hibit melanoma cells growth, as previously observed [21].
Alterations in cell cycle progression are indeed important
events in cancer development and hindering such altered
mechanism has been often used as a good strategy to in-
hibit tumour growth [27].
To investigate the possible molecular mechanisms trig-
gered by D6 treatments, we undertook a gene expression
profile analysis on melanoma cancer cells and fibroblast
normal cells. Our primary objective was to identify genes
that were up- or down-regulated in response to treatment,
and which could be related to the phenotypic outcome.
Two lists of regulated transcripts (0.5 > FC > 2), one for
LB24 melanoma cells and the other for BJ fibroblasts were
selected (Additional file 1-A and 2-A, respectively) and
subsequently analyzed by the IPA software. Considering
both the most significant functional categories and canon-
ical pathways (see Tables 2 and 3, respectively), the activity
of D6 compound in melanoma cells is certainly based on
either cell stress responses either activation/repression of
mechanisms regulating cell survival. Pathway analysis re-
vealed up-regulated effectors of cell stress response and
protein degradation as well as down-regulated gene prod-
ucts controlling cell proliferation (see Figure 3). The acti-
vation of cell defence pathways observed on melanoma
cells (Table 3, pathways 1–3) indicates that D6 treatment
causes important stimulation of the cellular stress re-
sponse, with a strong induction of HSPs, which in turn af-
fects cell survival and drives toward cell death [28-30]. In
physiological or pathological conditions, cellular stress
leads to transport and accumulation of damaged proteins
in the endoplasmic reticulum where they should be
repaired or committed to degradation. This stimulates the
over-expression of chaperons and HSPs that perform a sort
of quality control and drive seriously damaged proteins to
ubiquitination and proteasome degradation. When endo-
plasmic reticulum functions are strongly compromised, this
organelle triggers apoptotic signals in order to eliminate the
irreversibly damaged cell [31]. In our model, several HSPs
genes show to be up-regulated (see Table 3), and HSPA6 is
the most over-expressed transcript (FC = 368.61, Table 4). It
codifies for the stress inducible Hsp70B’ protein, normallyunder-expressed or absent in most cell types, whose expres-
sion is strictly linked to that of Hsp72 (gene HSPA1A, FC
= 20.35, Table 4); both these proteins have a key role in me-
diating cell survival during endoplasmic reticulum
proteotoxic stress conditions [32]. One could speculate that
their huge increase of expression levels following D6 treat-
ment could be related to the extreme endoplasmic
reticulum stress response that finally directs melanoma
cells to death by triggering apoptosis. In support of this hy-
pothesis, our analysis evidenced a strong induction of the
DDIT3 gene (FC = 11.1, Table 4), also known as growth ar-
rest and DNA damage-inducible gene 153 (GADD153),
which is one component of the ER stress-mediated apop-
tosis pathway [25]. Increased expression of GADD153 by
curcumin has been previously reported as one of the first
steps toward apoptosis in colon cancer cells [33], thus
confirming a possible contribution in this sense in D6
treated melanoma cells also.
Analogously, D6 stimulated cell stress response path-
ways in fibroblasts, but at a lower level compared to mel-
anoma cells (Additional file 2-C). This is confirmed by the
over-expression of single genes - like several HSPs and
DDIT3 (Table 4), which is presumably milder or not suffi-
cient to promote cell death [21].
One noteworthy feature occurring in melanoma cells
upon D6 treatment - as evidenced by IPA - is an up-
regulation of the p53 signalling pathway (Figure 3). The
p53 tumour suppressor protein is a key transcriptional
regulator that responds to a variety of cellular stresses and
controls key cellular processes such as DNA repair, cell-
cycle progression, angiogenesis, and apoptosis. The p53
protein thus acts like a “driver”, which can either save in-
jured cell by inducing damaged DNA repair and let it to
re-enter cycle or sacrifice it by stimulating both cell cycle
arrest and apoptosis [34,35]. In our model, up-regulation
of p53 signalling pathways seems to have a key role in me-
diating both antiproliferative and pro-apoptotic effects of
D6 on LB24 melanoma cells (see Additional file 4). Indeed,
a strong up-regulation of some p53 target genes has been
detected and could explain the anticancer effects of D6:
CDKN1A and GADD45A/B - that are strong inhibitors of
cell cycle G2/M transitions [36,37], might be responsible
for the block of cell cycle at G2 phase, and Noxa - a pro-
apoptotic BH3-only protein of the Bcl-2 family, may ac-
count for the apoptotic cell death [38]. As a confirmation
of this, the expression of CDKN1A gene codifying for the
CDK inhibitor p21 is about 20 times higher in treated
melanoma cells (FC = 19.35, Table 4). The p21 protein be-
longs to the Cip/Kip family of inhibitors and inactivates
CDK-cyclin complexes [36,39]. In our system, it seems to
regulate large part of melanoma cells response to D6 com-
pound, being a component of most pathways identified by
IPA (Table 3, pathways 4, 5, 6, 10, 11, 13, 15, 19, and 23;
see also Additional files 3, 4, 5, 6, 7, 8, 10, 11, 12).
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ively FC = 7.78 and FC = 7.47; see Table 4) also appears to
influence several growth controlling pathways (Table 3,
pathways 4, 5, 6, 10, 11, and 26; see Additional files 3, 4, 5,
6, 7). Proteins encoded by these two stress induced genes
are involved in regulation of growth and apoptosis and
may cooperate in inhibiting cell growth [37,40]. Over-
expression of the BH3-only Noxa protein codified by the
PMAIP1 gene (FC = 6.08, Table 4) suggests that D6 in-
duced apoptosis could be partially p53 dependent. Noxa
and Puma (p53-upregulated modulator of apoptosis) pro-
teins are in fact direct targets in p53-mediated apoptosis
at mitochondrial level [38,41], functioning as “sensors” for
apoptotic signals. Thus, increased Noxa levels could par-
ticipate in initiating the apoptotic cascade in D6 treated
melanoma cells. Supporting this hypothesis, a slight up-
regulation of the TP53BP2 gene has been reported in our
melanoma model (FC = 2.36, Table 4). This gene encodes
for ASPP2, a member of the ASPP (apoptosis-stimulating
protein of p53) family of p53 interacting proteins, which
regulate the apoptotic function of p53 and its family mem-
bers, p63 and p73. Biochemical and genetic evidences have
shown that ASPP1 and ASPP2 activate the apoptotic but
not the cell-cycle arrest function of p53 [42]. The in-
creased levels of ASPP2 protein observed in D6 treated
melanoma cells might thus induce p53 to trans-activate its
pro-apoptotic target genes, resulting in the observed
over-expression of Noxa, and subsequent activation of
mitochondrial intrinsic apoptosis. Another evidence of
pro-apoptotic signals in D6 treated cells expression pro-
file is the over-expression of the BCL10 gene (FC = 3.93,
Table 4), encoding for a pro-apoptotic member of the
Bcl2 family proteins. Bcl10 protein contains a caspase
recruitment domain (CARD) motif and promotes the
activation of caspase-9 [26].
The p53 signalling pathway has resulted to be signifi-
cantly affected also in fibroblasts (Additional file 2-C), be-
ing CDKN1A and GADD45 A/B partially up-regulated.
Again, this molecular response in fibroblasts is weaker
than that in melanoma cells (CDKN1A FC = 4.29, Table 4),
without causing in normal cells block of proliferation or
cell death.
Our analyses pointed out a down modulation of cell
cycle regulators cyclin B1, cdc25B, and CDK4 (Table 4),
which certainly contributes to the inhibition of cell prolif-
eration exerted by D6 on melanoma cells. Block of cell
cycle in G2/M phase perfectly matches with a decrease in
expression of both cyclin B (the mitotic switching cyclin)
and cdc25 (the CDK1 activating phosphatase), whereas
the decrease in CDK4 expression indicates that cells lack
entering the cell cycle while are driven to age and die [39],
as demonstrated by the G1 cell population decrease after
D6 treatment (see Figure 2). Interestingly, a lower or ab-
sent down-modulation of these mitosis promoters hasbeen evidenced in fibroblasts (Table 4), suggesting that D6
treatment specifically inhibits cell proliferation pathways
in melanoma cells.
Another gene down-modulated by D6 in melanoma
cells (and not in fibroblasts) is the CCNF gene (FC = 0.24,
Table 4), codifying for cyclin F, the founding member of
the F-box protein family [43]. In addition to an F-box do-
main, cyclin F contains a cyclin-box domain, but, in con-
trast to typical cyclins, it does not bind or activate any
cyclin-dependent kinases (CDKs). However, like other
cyclins, cyclin F protein levels vary during the cell division
cycle, peaking in G2. During G2, cyclin F is involved in
ubiquitination and degradation of proteins [44] as well as
in spindle formation and it is required for the fidelity of mi-
tosis and genome [45]. In our system, down-modulation of
such a protein is in agreement with the block of cell cycle
in G2/M phase demonstrated by cytofluorimetry (Figure 2).
A further contribution to D6 anticancer activity on mel-
anoma cells is given by the down-modulation of the c-KIT
proto-oncogene (FC = 0.30, Table 4). The c-kit protein be-
longs to class III receptor tyrosine kinases; its extracellular
domain binds the SCF (stem cells factor) to stimulate sev-
eral processes, including melanogenesis, gametogenesis,
and haematopoiesis [46]. The c-KIT up-regulation is often
associated with increased cell proliferation; its down-
regulation in D6 treated melanoma cells was confirmed by
western blot analysis (Figure 4C).
One could also hypothesize that a big contribution to
the anticancer activity of D6 is given by down-regulation
of both phosphatidylinositol 3-kinase (PI3K) and NF-kB
signalling pathways. There is growing evidence that activa-
tion of the PI3K/Akt pathway plays a significant role in
melanoma (reviewed in [47]). Our results are consistent
with an inhibition of PI3K/Akt pathway activation in mel-
anoma cells following D6 treatment. As also confirmed by
western blot analysis, a decreased expression of the
PIK3R2 gene (FC = 0.48, Table 4), an almost complete de-
pletion of the PI3K protein, and a 75% decrease of acti-
vated phospho-Akt have been observed in D6 treated cells
(Figure 4C). In addition, a slight up-modulation of PTEN
(Akt antagonist) gene expression was detected in our
study (FC = 1.45, data not shown). The IκB kinase (IKK)/
NF-κB signalling pathway is also often altered in tumours
and NF-κB can affect all six hallmarks of cancer through
the transcriptional activation of genes associated with cell
proliferation, angiogenesis, metastasis, tumour promotion,
inflammation and suppression of apoptosis (reviewed in
[48]). PI3K and NF-kB signalling pathways are functionally
linked, being NF-kB possibly activated by Akt kinase [49].
Our results show that, similarly to PIK3R2, NFKB1 gene
expression is down-regulated by D6 in melanoma cells
(FC = 0.47), but it is unclear whether this could be due to
the PI3K/Akt signalling repression. Deeper investigations
should be made to shed light on this molecular event.
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kB pathways are both involved in curcumin anti-tumour
activity [50] and inhibition of NF-kB activation may ac-
count for curcumin efficacy on cancer cells [18] and, specif-
ically, on human melanoma cells [19,20]. As a consequence,
it is likely that the curcumin analogue D6 shares some
mechanisms of action with its natural compound, being
even more effective in inhibiting tumour cells growth [21].
It is noteworthy that neither PIK3R2 nor NFKB1 genes ex-
pression was modulated in D6 treated normal fibroblasts
(Table 4). Based on these considerations, we can postulate
that PI3K and NF-kB signalling down-regulation is strongly
related to the anticancer activity of D6 on melanoma cells.
A further consideration may be done about a possible re-
lationship between NFKB1 under-expression and p53 sig-
nalling up-regulation. An intense crosstalk exists among
these two transcription factors that activate the expression
of genes with opposite functions. They are indeed competi-
tors for the transcriptional coactivator p300/CBP [51] and,
depending upon which of them (NF-κB or p53) recruits
this protein, different downstream pathways will be acti-
vated, resulting in either cell proliferation or growth arrest
and apoptosis [52]. To this regard, a recent report by
Sen and colleagues [53] demonstrated that curcumin re-
verses doxorubicin resistance in breast cancer by inhibiting
NF-κB activation and thus rescuing p300 coactivator,
which in turn becomes available to the p53 transcription
factor, and finally allows p53-dependent transactivation of
proapoptotic proteins such as Bax, PUMA and Noxa.
Based on these observations down-regulation of NF-κB by
D6 would make the coactivator p300 available for recruit-
ment by p53, thus favouring transactivation of its target
genes that triggers antiproliferative and proapoptotic activ-
ity. This could be a very interesting feature of D6 because
its potentiality to both inhibit NF-κB and, at the same time,
rescue p53 signalling could be exploited either for direct
therapeutic interventions against cancer, but also in
combined therapies in order to sensitize resistant cancer
cells to chemotherapeutic agents that can stimulate apop-
tosis by inducing DNA damages and triggering p53
apoptotic signals.
In summary, based on gene expression profile analysis re-
sults, we can speculate that different molecular mecha-
nisms may contribute to the anticancer effect of D6 in
melanoma cells: i) the induction of a cell stress response
that triggers the ER stress-mediated apoptosis pathway; ii)
the up-regulation of p53 signalling, which promotes p21-
and GADD45-dependent cell cycle arrest as well as mito-
chondrial apoptosis based on Noxa over-expression; iii) the
down-modulation of several growth signals, like both PI3K
and NF-kB pathways, and c-kit receptor. The diagram in
Figure 5 summarizes the major gene expression changes in-
duced by D6 in melanoma cells and hypothesizes the pos-
sible intervention of these changes in depicting cellular fate.Conclusions
Altogether, our findings contribute to unveil the molecular
mechanisms underlying the anti-tumour activity of D6 in
melanoma cells. Based on such results, we can speculate
that: a) p53 protein may play a key role in sustaining the
anticancer effects exerted by D6 on melanoma cells; b) in-
duction of strong cell stress responses may contribute
to the reinforcement of the proapoptotic trend of p53 sig-
nalling; and c) down-modulation of several growth signals
(c-kit, PI3K/Akt and NF-kB), as well as the under-
expression of cell cycle regulators (cyclin B, cdc25 and
CDK4) might be involved in cell growth inhibition. This
last aspect seems to be peculiar of the response to D6
treatment in melanoma cells, being absent in D6-treated
fibroblasts expression profile.
Although our analyses were not exhaustive, data here
presented strongly indicate that a huge amount of molecu-
lar changes does participate in determining the molecular
mechanism of action of D6 on melanoma cells. Gene ex-
pression profile analyses on additional melanoma cell lines
are currently in progress, in order to either confirm our
findings in a larger samples’ collection or evaluate the
effects of D6 on both primary and metastatic tumour
derived cell lines.
Methods
Cell cultures and D6 treatments
Malignant melanoma LB24Dagi (LB24) cell line was
obtained from the Department of Molecular and Cellular
Biology at the Istituto Dermopatico dell'Immacolata (IDI)
in Rome (Italy). Normal human fibroblast BJ (CRL-2522)
were purchased from the American Type Culture Collec-
tion (ATCC). All cells were grown in RPMI (Invitrogen,
Carlsbad, CA, USA) media, supplemented with 10% FBS
and penicillin-streptomycin (100 IU/50 μg/ml), as described
[54]. The αβ-unsaturated ketone D6 [(3E,3'E)-4,4'-(5,5',6,6'-
tetramethoxy-[1,1'-biphenyl]-3,3'-diyl)bis(but-3-en-2-one)]
(Figure 1A) has been synthesized in our lab as previously
described [21]. Stock solution of D6 was prepared by dis-
solving D6 in DMSO to a final concentration of 100 mM
and stored at −20°C. Working solutions of D6 were
prepared daily as previously described [21]. Cells were un-
treated or treated with medium containing 10 μM D6
for different times depending on the experiment, then
harvested with 0.25% trypsin-EDTA (Sigma-Aldrich, St.
Louis, MO, USA) and processed according to the protocol
of the specific analysis they have been submitted.
D6 cellular uptake
Melanoma cells were plated in T25 tissue culture flasks
(8 × 105 cell/flask) in complete medium; after 24 hours
cells were treated or untreated with 10 μM D6 for 1, 2,
4, 6 or 24 hours. At each time, cells were harvested with
0.25% trypsin-EDTA solution (Sigma-Aldrich, St. Louis,
growth factor
PI3K
Figure 5 Summary. The diagram summarizes the major gene expression changes induced by D6 in melanoma cells, outlining their possible role
in determining cell fate. Up-regulated proteins are represented in red gradations, while down-regulated ones are in green. Arrow-head lines
indicate molecular activation; blunt-head lines indicate inhibition.
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To achieve D6 extraction, cells in methanol were soni-
cated for 15 min and the cell lysates were centrifuged at
10,000 rpm for 5 min [55]. The supernatants were trans-
ferred and stored at −20°C pending analysis. Immedi-
ately prior to analysis, the samples were warmed up to
room temperature. After vortexing and centrifugation,
100 μl of the sample were filtered and transferred to a
HPLC vial for LC/MS analysis.
LC/MS analysis
LC-grade methanol, acetonitrile, and acetic acid (AA)
were purchased from Mallinckrodt J.T. Baker (Deventer,
Holland). Water was purified by a Milli-Q Academic Sys-
tem from Millipore (Bedford, MA, USA). Syringe filters
(Surfactant Free Cellulose Acetate 0.2 μm 0.13 mm) were
purchased from Nalgene Company (Rochester, NY, USA).
Stock solutions of D6 were prepared by dissolving 5 mg
of D6 in 10 mL of DMSO (final concentration 500 μg/mL).
Stock solutions of D6 were stored at - 20°C in high-density
polypropylene cryogenic-vials. Working solution of D6 was
prepared daily at the concentration of 100 nM by dilutingan aliquot of the stock solutions with the solvent system
(Eluent A) and was used to spike samples. Standard curves
solutions of D6 at six different concentrations (6.25, 12.50,
25, 50 or 500 nM.) were obtained by adding appropriate
concentrations of working solution in samples and solvent
system. A 1100 series LC/MSD system (Agilent Technolo-
gies, Palo Alto, CA, USA) equipped with a diode-array de-
tector and an autosampler (G1313A) was used for LC
separation. Chromatographic separation was achieved using
a Polar Plus column (150 mm×2.1 mm, 3 m) (Phenomenex,
Torrance, CA, USA) fitted with a 3 μ Polar Plus security
guard cartridge (4 mm×2.1 mm) (Phenomenex, Torrance,
CA, USA). The column temperature was maintained at
35°C. The mobile phase consisted of Eluent A water with
0.1% HOAc and Eluent B acetonitrile. The separation was
performed in a run time of 20 min under gradient condi-
tions with a flow rate of 0.3 mL/min and was followed by
clean-up and equilibration stage. The gradient elution
ranged from 35% (t = 0 min) to 65% acetonitrile (t = 20
min). The injection volume was 10 μL. Mass spectromet-
ric detection was performed using an Agilent G1946
(MSD 1100) single stage quadrupole instrument equipped
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source. The system was calibrated with the procedures
provided by Agilent; the mass spectrometer was optimized
with an infusion of 0.5 μg/mL D6 solution at a flow rate of
100 μL/min. The LC/MS system was programmed to di-
vert column flow to waste for 2.5 min after injection, after
which time flow was directed into the mass spectrometer
that operated in positive ion mode. For quantitative meas-
urement of analytes, selected ion monitoring (SIM) was
employed. In the ESI ion source, D6 formed predomin-
antly the ion at m/z 411 ([M+H]+). The following ESI
conditions were applied: drying gas (nitrogen) heated at
350°C at a flow rate of 9.5 L/min; nebulizer gas (nitrogen)
at a pressure of 42 psi; capillary voltage in positive mode
at 3500V; fragmentor voltage at 70V.
Cell cycle progression analysis
LB24 cells were plated in 6-well plates (8 × 105 cells/well),
let grown overnight and then treated with either 5 μM or
10 μM D6 for 24 hours. After treatments the cells were
harvested with trypsin /EDTA and washed with PBS. Pel-
lets were resuspended in 70% cold ethanol and stored
at −20°C until analysis. On the day of analysis, ethanol was
removed by centrifugation; pellets were washed with PBS
and resuspended in 1 ml of PBS containing 50 μg/mL
Propidium Iodide, 100 μg/mL ribonuclease and 100 μg/mL
sodium citrate (all from Sigma-Aldrich, St. Louis, MO,
USA). Samples were then incubated for 30 min at 4°C in
the dark and analyzed by flow cytometry using FACS
Canto II (BD Biosciences, San Jose, CA, USA). Data ana-
lysis was performed using the ModFit LT 3.0 software
(Verity Software House).
Gene expression profile analysis
Total RNA was isolated from LB and BJ cells, untreated
or treated with 10 μM D6 for 16 hours, using AllPrep
DNA/RNA Mini kit (Qiagen, Inc., Chatsworth, CA) for
a total of 12 RNA samples (4 samples in triplicate: LB-C
1-3, LB-D61-3, BJ-C1-3, BJ-D61-3). The amount of the
total RNA was detected using a NanoDrop 2000
(Thermo Fisher Scientific) and the quality was evaluated
by agarose gel electrophoresis. The total RNA samples
were normalized and, the mRNAs were amplified and
labeled using IlluminaW TotalPrep™ RNA Amplification
Kit (Ambion®). The system uses the in vitro transcrip-
tion (IVT) technology, based on the RNA amplification
protocol developed by James Eberwine and coworkers
[56]. The first reaction of the IVT is a reverse transcrip-
tion of mRNAs, performed using an oligo(dT) primer
tagged with a phage T7 promoter, and convert the
mRNA fraction to single-stranded cDNA. Then, a
Second-Strand Synthesis reaction converts the single-
stranded cDNA in double-stranded cDNA. This prod-
uct becomes the template for the in vitro transcriptionperformed using a T7 RNA Polymerase and Biotin-NTP
mix. The final results of the three reactions are hun-
dreds to thousands of biotinylated, antisense RNA cop-
ies of each mRNA per sample. According to the
manufacturer’s protocol, labeled cRNAs were quanti-
fied, 750 ng of each sample were denaturated at 65°C
for 5 min and hybridized on a HumanHT-12 v3 Expres-
sion BeadChip (IlluminaW) at 58°C overnight. Each well
targets 48,803 human probes, representing the whole
pool of human expressed genes. After stringency wash-
ing, the signal was developed with streptavidin-Cy3, the
array slide was dried by centrifugation and scanned
using iScan System (IlluminaW). Images were processed
and signals were quantified and normalized using
GenomeStudio software (IlluminaW). Probes with detec-
tion p-value > 0.05 in more than 9 out of 12 samples
were excluded from the statistical analysis.
Statistical analysis
Statistical analysis was carried out on probes that showed
p-values < 0.05 in 9/12 samples, by using the BRB-Array
Tools from Biometric Research Branch of National Cancer
Institute – NIH (USA). We identified genes that were dif-
ferentially expressed as an effect of D6 administration
using a random-variance t-test. The random-variance t-
test is an improvement over the standard separate t-test as
it permits sharing information among genes about within-
class variation without assuming that all genes have the
same variance [57]. Genes were considered statistically sig-
nificant if their p–value was less than 0.001. A stringent
significance threshold was used to limit the number of
false positive findings. A per gene FDR was also computed
using a univariate permutation test. Briefly, class labels of
the samples were randomly permuted N times. For each
gene, the permutation p-value is defined as a proportion
of permutations for which the p-values of the univariate
test are smaller than the p-value computed for the original
labeling. Data were further filtered by fold change (FC)
considering as differentially expressed probes only those
showing 0.5 > FC > 2. The results of the tests are reported
in the Additional file 1-A (LB24 melanoma cells) and 2-A
(BJ fibroblasts), tabulated along with relevant statistics and
hyperlink to gene annotations from the NCBI Entrez gene
database. Probes passing the tests were analysed by
Ingenuity Pathway Analysis (IPA) software which per-
forms a gene set enrichment analysis and groups genes by
biological functional categories and canonical pathways.
The p-value reflects the significance of the enrichment of
input genes in each functional category or pathway.
Western blot
Cells were plated in T75 tissue culture flasks in complete
medium and grown to semi-confluence, then were treated
for 24 hours with medium containing or not 10 μM D6.
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Ca++/Mg++ (Sigma-Aldrich, St. Louis, MO, USA), and
then lysed with lysis buffer (50 mM Tris HCl pH 7.5, 5
mM EDTA, 100 mM NaCl, 1 mM Na4P2O7, 1% Triton
X100) plus protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO, USA). Protein concentration was determined
by the QuantiPro BCA Assay Kit (Sigma-Aldrich, St.
Louis, MO, USA). Protein lysates (30 μg proteins per lane)
were resolved onto 10% or 12% NuPAGEW NovexW Bis-
Tris Mini Gels and transferred by iBlot™ Dry Blotting
System to iBlotW Gel Transfer Stacks Nitrocellulose, Mini
(all from Invitrogen). The membranes were then incu-
bated with primary antibodies over night at 4°C. Primary
antibodies used were: mouse monoclonal antibodies against
p21, cyclin B1, cdc25, PI3-kinase p85β, c-kit, GAPDH or
rabbit polyclonal antibodies against GADD45A, Noxa, p-
AKT 1/2/3 (Ser 474), all from Santa Cruz Biotechnology
Inc. Detection was achieved by HRP-conjugated anti-
mouse (Chemicon, Billerica, MA, USA, 1:10,000) or HRP-
conjugated anti-rabbit (Santa Cruz Biotech, 1:1,000,000)
antibodies. Immune complexes were visualized with
the use of an enhanced chemiluminescence system (ECL
Advance™, Amersham International). Protein levels were
quantified by ImageJ software [58] and normalized over
(ratio) the GAPDH protein levels used as internal control.Additional files
Additional file 1: Melanoma cells: gene expression profile results.
Excel file composed of three sheet: 1-A, 1-B, 1-C. 1-A: List of 1173 probes
differentially expressed in LB24Dagi melanoma cells after 16 hours of
exposure to 10 μM D6. The list resulted from the statistical analysis
performed by using the BRB-Array Tools as described in the Methods
section. Data were filtered by fold change (FC) considering as differentially
expressed probes only those showing 0.5 > FC > 2. In column C (Gene
symbol) hyperlink to gene annotations from the NCBI Entrez gene database
are supplied. 1-B: List of bio-functional categories, identified by Ingenuity
Pathway Analysis (IPA) software by analysing the 1173 transcripts modulated
in 10 μM D6 treated LB24Dagi melanoma cells (column A). Function
annotations (column B), number of genes of the input list involved in each
functional category (column E) and their symbol (column F) are shown in
the table. Right-tailed Fisher’s exact test has been performed to calculate a
p-value (column C) determining the probability that each biological function
assigned to the selected transcripts was due to chance. p-values were
adjusted for multiple comparisons using the Benjamini-Hochberg correction
(column D). 1-C: List of canonical pathways, identified by IPA software by
analysing the 1173 transcripts modulated in 10 μM D6 treated LB24Dagi
melanoma cells (column A). p-values (calculated using Fisher’s exact test)
reflect the probability that the association between the genes in the dataset
and the canonical pathway is explained by chance alone (column B). The
ratios in column C represent the number of molecules in a given pathway
that meet cut-off criteria, divided by total number of molecules that make
up that pathway. Genes of the input list involved in each pathway are
shown in column D.
Additional file 2: Fibroblasts: gene expression profile results. Excel
file composed of three sheets: 2-A, 2-B, 2-C. 2-A: List of 1883 probes
differentially expressed in BJ normal fibroblasts after 16 hours of exposure
to 10 μM D6. The list resulted from the statistical analysis performed by
using the BRB-Array Tools as described in the Methods section. Data
were filtered by fold change (FC) considering as differentially expressed
probes only those showing 0.5 > FC > 2. In column C (Gene symbol)hyperlink to gene annotations from the NCBI Entrez gene database are
supplied. 2-B: List of bio-functional categories, identified by Ingenuity
Pathway Analysis (IPA) software by analysing the 1883 transcripts
modulated in 10 μM D6 treated BJ normal fibroblasts (column A).
Function annotations (column B), number of genes of the input list
involved in each functional category (column E) and their symbol
(column F) are shown in the table. Right-tailed Fisher’s exact test has
been performed to calculate a p-value (column C) determining the
probability that each biological function assigned the selected transcripts
was due to chance. p-values were adjusted for multiple comparisons
using the Benjamini-Hochberg correction (column D). 2-C: List of
canonical pathways, identified by IPA software by analysing the 1883
transcripts modulated in 10 μM D6 treated BJ normal fibroblasts (column
A). p-values (calculated using Fisher’s exact test) reflect the probability
that the association between the genes in the dataset and the canonical
pathway is explained by chance alone (column B). The ratios in column C
represent the number of molecules in a given pathway that meet cut-off
criteria, divided by total number of molecules that make up that
pathway. Genes of the input list involved in each pathway are shown in
column D.
Additional file 3: Cell cycle: G2/M DNA checkpoint regulation. pdf
file elaborated by Ingenuity Pathway Analysis (IPA) software. The diagram
schematizes the “Cell cycle: G2/M DNA checkpoint regulation” pathway
(n.° 4 in Table 3) found to be significantly down-regulated in D6 treated
melanoma cells. Up-regulated genes are represented in red gradations,
down-regulated genes in green gradations. Colour intensity for each
gene is proportional to its FC value.
Additional file 4: p53 signalling pathway. pdf file, elaborated by
Ingenuity Pathway Analysis (IPA) software. The diagram schematizes
the “p53 signalling” pathway (n.° 5 in Table 3) found to be significantly
induced in D6 treated melanoma cells. Up-regulated genes are
represented in red gradations, down-regulated genes in green
gradations. Colour intensity for each gene is proportional to its FC value.
Additional file 5: Hereditary breast cancer signalling. pdf file
elaborated by Ingenuity Pathway Analysis (IPA) software. The diagram
schematizes the “Hereditary breast cancer signalling” pathway (n.° 10 in
Table 3) found to be significantly down-regulated in D6 treated
melanoma cells. Up-regulated genes are represented in red gradations,
down-regulated genes in green gradations. Colour intensity for each
gene is proportional to its FC value.
Additional file 6: ATM signalling. pdf file elaborated by Ingenuity
Pathway Analysis (IPA) software. The diagram schematizes the “ATM
signalling” pathway (n.° 11 in Table 3) found to be significantly induced
in D6 treated melanoma cells. Up-regulated genes are represented in red
gradations, down-regulated genes in green gradations. Colour intensity
for each gene is proportional to its FC value.
Additional file 7: Role of BRCA1 in DNA damage response. pdf file
elaborated by Ingenuity Pathway Analysis (IPA) software. The diagram
schematizes the “Role of BRCA1 in DNA damage response” pathway (n.°
26 in Table 3) found to be significantly induced in D6 treated melanoma
cells. Up-regulated genes are represented in red gradations, down-
regulated genes in green gradations. Colour intensity for each gene is
proportional to its FC value.
Additional file 8: Role of CHK proteins in cell cycle checkpoint
control. pdf file elaborated by Ingenuity Pathway Analysis (IPA) software.
The diagram schematizes the “Role of CHK proteins in cell cycle
checkpoint control” pathway (n.° 27 in Table 3) found to be significantly
down-regulated in D6 treated melanoma cells. Up-regulated genes are
represented in red gradations, down-regulated genes in green
gradations. Colour intensity for each gene is proportional to its FC value.
Additional file 9: Mitotic roles of Polo-like kinase. pdf file elaborated
by Ingenuity Pathway Analysis (IPA) software. The diagram schematizes the
“Mitotic roles of Polo-like kinase” pathway (n.° 8 in Table 3) found to be
significantly down-regulated in D6 treated melanoma cells. Up-regulated
genes are represented in red gradations, down-regulated genes in green
gradations. Colour intensity for each gene is proportional to its FC value.
Additional file 10: Cyclins and cell cycle regulation. pdf file
elaborated by Ingenuity Pathway Analysis (IPA) software. The
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http://www.molecular-cancer.com/content/12/1/37diagram schematizes the “Cyclins and cell cycle regulation” pathway
(n.° 13 in Table 3) found to be significantly down-regulated in D6 treated
melanoma cells.
Up-regulated genes are represented in red gradations, down-regulated
genes in green gradations. Colour intensity for each gene is proportional
to its FC value.
Additional file 11: Molecular mechanisms of cancer. pdf file
elaborated by Ingenuity Pathway Analysis (IPA) software. The
diagram schematizes the “Molecular mechanisms of cancer” pathway
(n.° 23 in Table 3) found to be significant in D6 treated melanoma cells.
Up-regulated genes are represented in red gradations, down-regulated
genes in green gradations. Colour intensity for each gene is proportional
to its FC value.
Additional file 12: Cell cycle: G1/S Checkpoint regulation. pdf file
elaborated by Ingenuity Pathway Analysis (IPA) software. The diagram
schematizes the “Cell cycle: G1/S Checkpoint regulation” pathway (n.° 25 in
Table 3) found to be significantly down-regulated in D6 treated melanoma
cells. Up-regulated genes are represented in red gradations, down-regulated
genes in green gradations. Colour intensity for each gene is proportional to
its FC value.
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